Disc Medicine, Inc.
For the period ended Mar 31, 2026. Filed May 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 5, 2026
IRON$84.64+4.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
| Common Stock$0.0001 Par Value · Additional Paid-In · Accumulated OtherComprehensive · Accumulated · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Income (Loss) | Deficit | Equity | |
| Balance at December 31, 2025 | 37,890,616 | 4 | 1,249,043 | 965 | (510,186) | 739,826 |
| Issuance of common stock upon exercise of stock options | 67,811 | — | 1,010 | — | — | 1,010 |
| Issuance of common stock upon vesting of restricted stock units | 218,322 | — | — | — | — | — |
| Issuance of common stock under employee stock purchase plan | 13,715 | — | 687 | — | — | 687 |
| Stock-based compensation expense | — | — | 11,946 | — | — | 11,946 |
| Foreign currency translation adjustments | — | — | — | (10) | — | (10) |
| Unrealized loss on marketable securities | — | — | — | (1,526) | — | (1,526) |
| Net loss | — | — | — | — | (63,504) | (63,504) |
| Balance at March 31, 2026 | 38,190,464 | $4 | $1,262,686 | $(571) | $(573,690) | $688,429 |
| Common Stock$0.0001 Par Value · Additional Paid-In · Accumulated OtherComprehensive · Accumulated · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Income | Deficit | Equity | |
| Balance at December 31, 2024 | 29,865,030 | 3 | 741,297 | 289 | (298,002) | $443,587 |
| Issuance of common stock upon exercise of stock options | 91,524 | — | 575 | — | — | 575 |
| Issuance of common stock upon vesting of restricted stock units | 83,672 | — | — | — | — | — |
| Issuance of common stock under employee stock purchase plan | 7,814 | — | 287 | — | — | 287 |
| Sale of common stock in underwritten offering, net of issuance costs of $15,321 | 4,533,182 | — | 234,003 | — | — | 234,003 |
| Sale of pre-funded warrants in underwritten offering, net of issuance costs of $615 | — | — | 9,386 | — | — | 9,386 |
| Stock-based compensation expense | — | — | 6,363 | — | — | 6,363 |
| Foreign currency translation adjustments | — | — | — | 14 | — | 14 |
| Unrealized gain on marketable securities | — | — | — | 232 | — | 232 |
| Net loss | — | — | — | — | (34,085) | (34,085) |
| Balance at March 31, 2025 | 34,581,222 | $3 | $991,911 | $535 | $(332,087) | $660,362 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.